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Division of Liver Diseases, Mount Sinai School of Medicine, New York, NY, USAA silent partner no longer – Sinusoidal endothelial cells in liver
homeostasis and diseaseA study in this month’s issue of the Journal illustrates the
growing appreciation for how non-parenchymal cells – in this
case liver sinusoidal endothelial cells – contribute to disease.
The term ‘non-parenchymal cells’ refers not only to endothelial
cells, but also to hepatic stellate cells macrophages and a host
of resident lymphocytes and immune cells within the liver, which
collectively comprise approximately 40% of the total number of
liver cells. Stellate cells have garnered most of our attention in
the past decade because of their major contribution to ﬁbrogen-
esis, and because of ready methods to isolate and characterize the
cells. Moreover, stellate cells love to grow in culture and thus
even mixed non-parenchymal cell cultures invariably become
dominated by stellate cells when plated in the presence of serum.
Macrophages, which in the liver have been traditionally called
‘‘Kupffer cells’’ based on the late 19th century description by
Kupffer [1], are also well appreciated. Moreover, we have adopted
an increasingly nuanced understanding of their heterogeneity
and divergent functions as a result of the identiﬁcation of many
cell surface markers, and advances in ﬂow cytometry methods
[2].
In contrast, the sinusoidal endothelial cell has been largely
overlooked, in part because its wispy presence in tissue sections
is easily disregarded, and also because the cell hates primary cul-
ture and is exquisitely sensitive to the stress of tissue disruption
and isolation. Nonetheless, an enlarging biology has emerged,
focused for the most part on their unique intracellular pores, or
fenestrae, and their contribution to portal hypertension [3]. ‘Cap-
illarization’ of sinusoids with loss of these fenestrae in liver dis-
ease has been recognized for almost 50 years [4], but the
functional consequences of defenestration and its impact on
sinusoidal homeostasis are only now being clariﬁed. The cells
are highly responsive to vascular mediators including vascular
endothelial growth factor (VEGF), nitric oxide (NO), endothelin,
thromboxanes, and prostaglandins that contribute to a dynamic
crosstalk with hepatic stellate cells in regulating blood ﬂow [3].
In fact, maintenance of sinusoidal fenestrations and prevention
of capillarization in vivo help preserve stellate cell quiescence
and minimize ﬁbrosis [5]. Conversely, liver injury provokes
changes in sinusoidal endothelial and stellate cells that amplify
each other’s pathogenic responses, leading to an accelerating pat-Journal of Hepatology 20
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The paper by Drs. Rodríguez-Villarupla and colleagues in this
issue of the Journal builds on this model of paracrine regulation
and introduces a new intracellular mediator of sinusoidal cell
responses – peroxisome proliferator activated receptor alpha
(PPARa). This molecule is perhaps the best-characterized among
members of the nuclear hormone superfamily, and its classical
function is to increase fatty acid oxidation by combining with
the RXR nuclear receptor to stimulate lipid metabolism-regulat-
ing genes [6]. Ligands for PPARa fall into two main groups – syn-
thetic xenobiotics (exogenous) and biological molecules
(endogenous). The best-known synthetic ligands are the ‘ﬁbrates’
(e.g. cloﬁbrate, fenoﬁbrate), which are typically prescribed as
hypolipidemic agents, whereas the endogenous ligands are pri-
marily fatty acids and their derivatives. It is not surprising given
its role in lipid metabolism that most previous studies examining
PPARa biology in the liver have focused on hepatocytes. Yet,
more recent studies have identiﬁed effects of PPARa in improving
endothelial dysfunction in cardiac and vascular tissues [7,8], and
have uncovered PPARa target genes that regulate blood ﬂow (e.g.
thromboxanes) to account for some of these effects.
In this context, it was logical to explore the potential contribu-
tion of PPARa activity to hepatic blood ﬂow regulation in the
Rodríguez-Villarupla study. Mice in which hepatic ﬁbrosis was
established by 3 weeks of CCl4 administration were then treated
with either a control diet or one containing a pharmacologic con-
centration of fenoﬁbrate for an additional week, and the extent of
hepatic ﬁbrosis and impact on hemodynamics were assessed.
Remarkably, PPARa activation led to reduced hepatic ﬁbrosis
and portal pressure despite only a week of therapy, which was
associated with improved vasodilatory responses to acetylcholine
and increased bioavailability of nitric oxide (a vaso-relaxing com-
pound) in endothelial cells from treated mice.
These ﬁndings are very appealing because ﬁbrates are already
widely prescribed to patients with hyperlipidemia, and therefore
their safety is established. Human trials would seem like a logical
next step. However, the results really represent an initial series of
observations that merit further exploration ﬁrst. Speciﬁcally, the
cellular targets of PPARa actions are not clariﬁed, as the effects
could represent solely the direct impact of fenoﬁbrate on endo-
thelial cells, or more likely the added effects of the drug on PPARa
activity in hepatocytes and/or macrophages, which also express
PPARa, but probably not on hepatic stellate cells, since prior
studies indicate that they are not responsive to PPARa ligands
[9,10]. How, then, does PPARa activation reduce ﬁbrosis? Based12 vol. 56 j 1001–1002
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on the recent study by Xie et al. [5], an attractive hypothesis is
that restoration of normal endothelial responses (i.e. reversal of
capillarization) drives quiescence of stellate cells through an
unknown mechanism. This would imply that in doing so, net pro-
tease activity is increased to help resorb accumulated scar and
reduce ﬁbrogenic gene expression. These effects of PPARa are
likely to be indirect through induction of PPARa-regulated genes,
either in endothelial cells, Kupffer cells and/or hepatocytes. The
most elegant approach to sort out these possibilities would be
to generate mice with cell-speciﬁc knockout of PPARa. Cell-spe-
ciﬁc depletion could be accomplished by using a Cre-lox strategy
in which mice expressing Cre recombinase driven by a cell type-
speciﬁc promoter (e.g. albumin-Cre for hepatocytes), could be
crossed with animals in which the PPARa allele is ﬂanked by LoxP
sites (i.e. ‘ﬂoxed’). This would lead in the progeny to Cre-medi-
ated recombination that deletes PPARa only in cells in which
the promoter that is driving Cre expression is active. Such a strat-
egy would enable investigators to determine in which cell type(s)
fenoﬁbrate is exerting its actions not only in regulating vasoregu-
lation, which appears to be a direct effect on sinusoidal endothe-
lium, but also in ﬁbrosis, in which the effect on stellate cells is
likely to be indirect.
Based on the Rodríguez-Villarupla study and related papers, it
is clear that the sinusoidal endothelial cell represents a fertile
focus for more studies whose ﬁndings could directly improve
treatments for liver disease. Although culture and characteriza-
tion methods have been more challenging for this cell type,
new tools are emerging to overcome these obstacles, including
an immortalized murine sinusoidal endothelial cell line [11],
identiﬁcation of new cell surface markers, and characterization
of endothelial cell-speciﬁc promoters [12]. In addition to their
role in vasoregulation, sinusoidal endothelium are also a driving
force behind angiogenesis in liver development, regeneration,
and cancer [13]. They should no longer be viewed as a silent part-
ner in liver homeostasis.1002 Journal of Hepatology 2012Conﬂict of interest
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